Emergent BioSolutions: Frank Vargo to be interim CFO
Frank Vargo's approved interim pay adds $3,850 per pay period to his current $328,000 base salary beginning January 1, 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Emergent BioSolutions Inc. (EBS) announced a finance leadership transition: Richard Lindahl will step down as chief financial officer and principal financial and accounting officer effective December 31, 2026, and serve as an advisor through March 31, 2027, when he is scheduled to retire. Frank Vargo, the company’s vice president and treasurer, will become interim chief financial officer and principal financial and accounting officer on January 1, 2027.
The board approved additional interim compensation of $3,850 per pay period for Vargo beginning January 1, 2027, in addition to his current base salary of $328,000. His salary, bonus and equity awards will remain commensurate with his seniority and position before the appointment and will be reviewed on the same cycle as those of other executive officers. Lindahl will assist with the transition, including preparing and filing the Annual Report on Form 10-K for the year ending December 31, 2026.
Filing Explained
The filing adds that Lindahl’s compensation as an advisor will be materially consistent with his current compensation during the advisory period ending
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Additional interim compensation: $3,850 per pay period
Current base salary: $328,000
Lindahl's service as CFO: Over eight years
+1 more
4 metrics
Additional interim compensation
$3,850 per pay period
Approved for Frank Vargo beginning January 1, 2027
Current base salary
$328,000
Frank Vargo
Lindahl's service as CFO
Over eight years
Company statement
Vargo's age
43
Company statement
Key Terms
principal financial and accounting officer, interim compensation pay, related party transactions
3 terms
principal financial and accounting officer financial
"principal financial and accounting officer effective December 31, 2026"
interim compensation pay financial
"approved interim compensation pay of an additional $3,850"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does EBS's CFO transition take effect?
Frank Vargo will become interim chief financial officer and principal financial and accounting officer on January 1, 2027. Richard Lindahl will step down from those roles effective December 31, 2026, and serve as an advisor through March 31, 2027, when he is scheduled to retire.
What interim compensation did EBS approve for Frank Vargo?
Emergent BioSolutions approved additional interim compensation of $3,850 per pay period for Frank Vargo beginning January 1, 2027, in addition to his current base salary of $328,000.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 16, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of incorporation) | Identification No.) | |||||||||||||
(Address of principal executive offices, including zip code)
(240 ) 631-3200
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 16, 2026, Emergent BioSolutions Inc. (the “Company”) announced that Richard Lindahl, the Company’s Chief Financial Officer, will step down from his role as the Company’s principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027. The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company’s Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027. Prior to his retirement date, Mr. Lindahl will assist with the transition of his responsibilities, including the preparation and filing of the Company’s Annual Report on Form 10-K for the year ending December 31, 2026. Mr. Lindahl’s compensation as an advisor will be materially consistent with his current compensation. The Company thanks Mr. Lindahl for over eight years of dedicated service to the Company as its Chief Financial Officer.
Frank Vargo, age 43, joined the Company in December 2019 as Director, Corporate FP&A and G&A. Mr. Vargo was named Vice President, Treasurer in November 2025. Prior to joining the Company, Mr. Vargo held roles of increasing responsibility in finance at Under Armor, Inc. and in the aerospace and defense industry. He holds an MBA from Texas A&M University and a bachelor’s degree in engineering from the Georgia Institute of Technology. In connection with his promotion to Interim Chief Financial Officer, the Company’s Board of Directors approved interim compensation pay of an additional $3,850 per pay period in addition to his current base salary of $328,000 for Mr. Vargo commencing January 1, 2027. Mr. Vargo’s salary, bonus and equity awards will remain commensurate with his seniority and position before his appointment as Interim Chief Financial Officer and will be reviewed on the same cycle as those of the Company’s other Emergent executive officers.
Mr. Vargo and his immediate family members are not party to any related party transactions for which disclosure would be required pursuant to Item 404(a) of Regulation S-K. There is no family relationship between Mr. Vargo and any of the Company’s directors or executive officers and no arrangements or understandings with other persons pursuant to which Mr. Vargo was selected as an officer.
A copy of our press release (the “Press Release”), dated October 16, 2026, announcing the transition is filed hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press release issued by Emergent BioSolutions Inc. on October 16, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EMERGENT BIOSOLUTIONS INC. | ||||||||
| Dated: October 16, 2026 | By: | /s/ Jessica Perl | ||||||
| Name: | Jessica Perl | |||||||
| Title: | Senior Vice President, General Counsel (Authorized Officer of Registrant) | |||||||
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
•Appointment of Frank Vargo, VP, Treasurer, to Interim CFO effective January 1, 2027
GAITHERSBURG, Md., October 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Company effective December 31, 2026. Frank Vargo, vice president, treasurer, will assume the role of interim chief financial officer effective January 1, 2027. To support a seamless transition, Rich will serve as a senior executive advisor from January 1 through March 31, 2027.
“On behalf of the Board of Directors and our colleagues, I want to thank Rich for his exceptional leadership, partnership and commitment to Emergent, and importantly, his dedication to our mission to protect and save lives,” said Joe Papa, president and chief executive officer of Emergent. “We are grateful that he will continue to advise the Company during the first quarter of 2027 as we complete this transition, and we wish him all the best in retirement. Since joining Emergent in 2019, Frank has been integral in driving our strategic priorities forward, and I am confident he will ensure continuity and disciplined financial stewardship as interim chief financial officer.”
Before coming to Emergent in 2018, Rich served as CFO of publicly traded best practices and technology solutions company CEB, SVP and treasurer of Sprint Nextel Corporation, and VP of finance at Pocket Communications, Inc., and held various positions at MCI Communications Corp. and Deloitte & Touche LLP. He currently serves on the board of directors of Compass Therapeutics, Inc.
“During my nearly nine years at Emergent, I am proud of the contributions our team made to the Company’s growth, the resilience we demonstrated through some extraordinarily challenging periods, and the progress we made in strengthening the business for the future,” said Lindahl. “I am deeply grateful to the Board, my colleagues and the many people across Emergent who made this such a rewarding chapter of my career, and I am committed to ensuring a smooth and successful transition. Looking ahead, I am excited to remain professionally engaged through board service and advisory work while making more time for family, friends, travel and personal pursuits.”
The leadership transition reflects Emergent’s continued execution of its multi-year transformation plan, which is focused on strengthening the business, improving operating performance and positioning the Company for long-term, sustainable growth.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements include statements regarding our plans for the office of the chief financial officer and the execution of our multi-year transformation plan. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements include statements regarding our plans for the office of the chief financial officer and the execution of our multi-year transformation plan. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com